Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

IMPORTANCE: Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately. OBJECT...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA
Glavni autori: Rollman, Jeffrey Eric, Heyward, James, Olson, Lily, Lurie, Peter, Sharfstein, Joshua, Alexander, G. Caleb
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439622/
https://ncbi.nlm.nih.gov/pubmed/30778596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.0235
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items